Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
Clinical, Cosmetic and Investigational Dermatology · 2023-02 · Volume 16 · 529-536
DOI: 10.2147/ccid.s402183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2023-02. Verfasst von Angelo Ruggiero und 5 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Angelo Ruggiero, Luca Potestio
Zitieren
APA
Ruggiero, A., Fabbrocicni, G., Cacciapuoti, S., Potestio, L., Gallo, L., & Megna, M. (2023). Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Clinical, Cosmetic and Investigational Dermatology, Volume 16, 529-536. https://doi.org/10.2147/ccid.s402183
Vancouver
Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Clinical, Cosmetic and Investigational Dermatology. 2023;Volume 16:529-536. doi:10.2147/ccid.s402183
BibTeX
@article{Ruggiero2023,
author = {Ruggiero, Angelo and Fabbrocicni, Gabriella and Cacciapuoti, Sara and Potestio, Luca and Gallo, Lucia and Megna, Matteo},
title = {Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2023},
volume = {Volume 16},
pages = {529--536},
doi = {10.2147/ccid.s402183}
}
EUVIMED